US expands prescribing recommendations for aspirinBMJ 1998; 317 doi: https://doi.org/10.1136/bmj.317.7167.1176 (Published 31 October 1998) Cite this as: BMJ 1998;317:1176
- Deborah Josefson
- San Francisco
The US Food and Drug Administration (FDA) has substantially expanded its official prescribing recommendations and labelling requirements for aspirin to increase use in ischaemic heart disease and stroke.
The effectiveness of aspirin in preventing heart attacks and limiting infarct size is widely known, but only about half of patients who have had a heart attack receive the drug, according to an advisory panel. Under the new ruling, …
Log in using your username and password
Log in through your institution
Sign up for a free trial